Introduction {#s1}
============

Oral cancers are the 10th most common cancer worldwide, with oral tongue squamous cell carcinoma (OTSCC) having the highest incidence.[@R1] Surgery and radiotherapy (RT), the mainstay treatments for OTSCC, impact on the patients\' quality of life and the 50% 5-year survival has remained unchanged for 40 years.[@R1]

Cancer stem cells (CSCs) have been proposed to be the origin of many cancers, including oral cavity squamous cell carcinoma (OCSCC). CSCs express the embryonic stem cell (ESC) markers OCT4,[@R2] NANOG,[@R3] SOX2,[@R2] SALL4[@R3] and STAT3,[@R4] the more 'downstream' CSC marker CD44[@R2] and the epithelial cell marker p63,[@R5] suggesting a diverse phenotype. The relative abundance and co-expression of these markers and their localisation within OCSCC remain unclear.

Immunohistochemistry {#s2}
====================

4 μm thick formalin-fixed paraffin-embedded sections of moderately differentiated OTSCC (MDOTSCC) samples from seven male and three female patients, aged 30--84 (mean 63.3) (see [online supplementary table](#SM2){ref-type="supplementary-material"} S1) were used for immunohistochemical (IHC) staining, as previously described.[@R6] All sections underwent single 3,3-diaminobenzidine (DAB) IHC staining for the primary antibodies NANOG, 1:500 (cat\#D73G4; Cell Signaling Technology, Danvers, Massachusetts, USA), SOX2, 1:500 (cat\#PA1-094; Thermo Fisher Scientific, Santa Cruz, California, USA), CD44, 1:1500 (cat\#MRQ-13; Cell Marque, Santa Cruz, California, USA), pSTAT-3, 1:100 (cat\#D3A7; Cell Signaling Technology), SALL4, 1:100 (cat\#6E3; Cell Marque) and OCT4, 1:30 (cat\#MRQ-10; Cell Marque), Bond Ready-To-Use p63 (cat\#NCL-p63; Leica, Newcastle, UK). To confirm co-expression of two proteins, representative slides of MDOTSCC (n=2) underwent immunofluorescent (IF) IHC staining using a combination of VectaFluor Excel anti-rabbit 594 (ready-to-use, cat\#VEDK-1594, Vector Laboratories, Burlingame, CA, USA) and Alexa Fluor anti-mouse 488 (1:500, cat\#A21202, Life Technologies) to detect combinations that included NANOG, SOX2 and pSTAT3 and VectaFluor Excel anti-mouse (ready-to-use, cat\#VEDK2488, Vector Laboratories) and Alexa Fluor anti-rabbit 594 (1:500, cat\#A21207, Life Technologies) to detect combinations that included OCT4 or SALL4. Positive control tissues used were human skin (for p63), tonsil (for CD44) and seminoma (for OCT4, NANOG, SOX2, SALL4 and pSTAT3).
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DAB IHC staining of MDOTSCC samples revealed expression of p63 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1A, brown), SALL4 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1B, brown), SOX2 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1C, brown), NANOG (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1D, brown), pSTAT3 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1E, brown) and CD44 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1F, brown) by cells predominantly localised to the tumour nests (TNs), distinct from the cells expressing OCT4 (see [online supplementary figure](#SM3){ref-type="supplementary-material"} S1G, brown) within the stroma, between the TNs.
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IF IHC staining demonstrated nuclear expression of p63 in cells within the TNs ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}A, green). SOX2 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}A, red) was expressed by the p63^+^ ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}A, green) immunoreactive (IR) cells. OCT4 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}B, green) and SOX2 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}B, red) were expressed by two distinct population of cells. SALL4^+^ ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}D, G, green) cells expressed NANOG ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}D, red) and SOX2 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}E, red). This SOX2^+^ ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}F, red) population also demonstrated membranous expression of CD44 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}F, green) and was also IR for pSTAT3 ([figure 1](#JCLINPATH2015203599F1){ref-type="fig"}G, red). Specificity of the primary antibodies was confirmed with the positive controls (data not shown).

![Representation of immunofluorescent (IF) immunohistochemical (IHC)-stained sections of 10 moderately differentiated oral tongue squamous cell carcinoma, demonstrating nuclear co-expression of the epithelial cell marker p63 (A, green) and the cancer stem cell (CSC) marker SOX2 (A, red), within the tumour nests. The SOX2^+^ population (B, red) was distinct from the CSC population that expressed OCT4 (B, green). The OCT4^+^ (C, green) cells were distinct from the CSC that expressed NANOG (C, red). Further staining with SALL4 demonstrated that the SALL4^+^ cells (D and E, green) also expressed NANOG (D, red) and SOX2 (E, red); this combination of the green and red stains displayed as orange (D and E). The SOX2^+^ (F, red) cells also expressed the membranous CSC marker CD44 (F, green). The CD44^+^ (G, green) cells also expressed the CSC marker pSTAT3 (G, red). Scale bars: 20 μm.](jclinpath-2015-203599f01){#JCLINPATH2015203599F1}

Nanostring mRNA analysis {#s3}
========================

Total RNA, isolated and quantified as previously described[@R6] from six snap-frozen MDOTSCC samples of the original cohort of 10 patients used for DAB IHC staining, was subjected to the NanoString nCounter gene expression assay (NanoString Technologies, Seattle, WA, USA) performed by New Zealand Genomics (Dunedin, New Zealand). Probes for the genes encoding P63 (NM_003722.4), CD44 (NM_001001392.1), OCT4 (NM_002701.4), NANOG (NM_024865.2) and STAT3 (NM_139276.2) and the housekeeping genes GUSB (NM_00181.3), CLTC (NM_4859.2) and HPRT1 (NM_000194.1) were used. Data were analysed by nSolver software (Nanostring Technologies).

NanoString transcriptional profiling of six MDOTSCC samples, normalised against the housekeeping genes, glucuronidase beta (GUSB), clathrin heavy chain (CLTC) and HPRT1, confirmed the presence of mRNA for p63, epithelial membrane antigen (EMA), CD44, STAT3, OCT4 and NANOG ([figure 2](#JCLINPATH2015203599F2){ref-type="fig"}).

![Copy number variants for mRNA transcripts in six moderately differentiated oral tongue squamous cell carcinoma for OCT4, SOX2, NANOG, STAT3 and p63 expressed relative to the housekeeping genes GUSB, CLTC and HPRT1.](jclinpath-2015-203599f02){#JCLINPATH2015203599F2}

In situ hybridisation {#s4}
=====================

Representative 4 μm thick formalin-fixed paraffin-embedded sections of three MDOTSCC samples were used for mRNA in situ hybridisation (ISH) staining, as previously described.[@R6] The probes used for OCT4 (NM_002701.4), NANOG (NM_024865.2), SOX2 (NM_003106), STAT3 (NM_139276.2) and SALL4 (NM_020436) were obtained from Affymetrix (CA, USA). Human seminoma tissue sections were used as positive controls.

ISH staining localised mRNA for OCT4 ([figure 3](#JCLINPATH2015203599F3){ref-type="fig"}A, red), SOX2 ([figure 3](#JCLINPATH2015203599F3){ref-type="fig"}B, red), STAT3 ([figure 3](#JCLINPATH2015203599F3){ref-type="fig"}C, red), NANOG ([figure 3](#JCLINPATH2015203599F3){ref-type="fig"}D, red) and SALL4 ([figure 3](#JCLINPATH2015203599F3){ref-type="fig"}E, red) to the nuclei of OTSCC epithelial-like cells. Specificity of the ISH probes was confirmed with positive staining in human seminoma (data not shown).

![Representative in situ hybridisation-stained formalin-fixed paraffin-embedded oral tongue squamous cell carcinoma sections demonstrating mRNA expression of OCT4 (A, red, *arrows*), SOX2 (B, red, *arrows*), STAT3 (C, red, *arrows*), NANOG (D, red, *arrows*) and SALL4 (E, red, *arrows*). Original magnification: ×1000.](jclinpath-2015-203599f03){#JCLINPATH2015203599F3}

Imaging {#s5}
=======

All DAB IHC-stained and ISH-stained slides were viewed and the images captured using an Olympus BX53 light microscope (Tokyo, Japan). All IF IHC-stained slides were viewed and the images captured using an Olympus FV1200 confocal laser scanning microscope and processed with cellSens Dimension 1.11 software using two-dimensional deconvolution algorithm (Olympus).

Discussion {#s6}
==========

The identification of a subpopulation of CSCs within MDOTSCC expressing p63, a marker of squamous epithelium, that also expresses the CSC marker CD44 and the ESC markers SOX2, OCT4, SALL4 and pSTAT3 in this study is novel. To the best of our knowledge, this is the first report demonstrating a separate subpopulation of CSCs that express OCT4 exclusively within MDOTSCC. Whether this represents a separate CSC or a 'normal' stem cell recruited into the tumour remains to be conclusively determined. The findings of at least two putative CSC subpopulations within MDOTSCC is novel and may potentially be explained by previous assumptions of these cells being at the invasive tumour front and thus in the transitory process of migrating from the TNs,[@R7] suggesting that the former originate from the latter. Alternatively, there are two distinct stem cell subpopulations within OTSCC, each playing a critical role in carcinogenesis.

Our intriguing findings of the cytoplasmic localisation of OCT4, SALL4, SOX2 and NANOG are consistent with reports on gliomas which have been attributed to disease specificity,[@R8] distinct from that of normal embryonic development. This observation merits further investigation.

Future work including characterisation of CSCs in well and poorly differentiated OTSCC using the same markers and the identification of their regulatory pathway(s) may uncover novel therapeutic targets.
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